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Background: Inflammation and increased ceramide concentrations characterise adipose tissue of obese women
with high liver fat content compared to equally obese women with normal liver fat content. The present study
characterises enzymes involved in ceramide metabolism in subcutaneous and intra-abdominal adipose tissue.
Methods: Pathways leading to increased ceramide concentrations in inflamed versus non-inflamed adipose tissue
were investigated by quantifying expression levels of key enzymes involved in ceramide metabolism.
Sphingomyelinases (sphingomyelin phosphodiesterases SMPD1-3) were investigated further using
immunohistochemistry to establish their location within adipose tissue, and their mRNA expression levels were
determined in subcutaneous and intra-abdominal adipose tissue from both non-obese and obese subject.
Results: Gene expression levels of sphingomyelinases, enzymes that hydrolyse sphingomyelin to ceramide, rather
than enzymes involved in de novo ceramide synthesis, were higher in inflamed compared to non-inflamed adipose
tissue of obese women (with high and normal liver fat contents respectively). Sphingomyelinases were localised to
both macrophages and adipocytes, but also to blood vessels and to extracellular regions surrounding vessels within
adipose tissue. Expression levels of SMPD3 mRNA correlated significantly with concentrations of different ceramides
and sphingomyelins. In both non-obese and obese subjects SMPD3 mRNA levels were higher in the more inflamed
intra-abdominal compared to the subcutaneous adipose tissue depot.
Conclusions: Generation of ceramides within adipose tissue as a result of sphingomyelinase action may contribute
to inflammation in human adipose tissue.
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Low grade systemic inflammation and insulin resistance
often occur together, and adipose tissue is a site of inflam-
mation in the insulin resistant state. In adipose tissue of
obese and insulin resistant subjects macrophage number
and inflammatory cytokine production are increased, while
adiponectin production is decreased [1]. The mechanisms
causing macrophage recruitment into adipose tissue are un-
clear, although adipocyte size has been implicated [1]. Fur-
thermore, macrophages are often found clustered in* Correspondence: rachel.fisher@ki.se
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reproduction in any medium, provided the or“crown-like structures” surrounding individual adipocytes
[2,3], which appear to be dead [2], suggesting that dead/
dying adipocytes may trigger macrophage influx, but the
reason for adipocyte death is unknown. Another theory is
that hypoxia may develop in regions of obese adipose tissue
distant from the vasculature, causing hypoxic adipocytes to
produce inflammatory cytokines and/or to die thus trig-
gering macrophage infiltration [4]. An interesting possibility
is that there are similarities between inflammatory path-
ways in obese/insulin resistant adipose tissue and the
atherosclerotic artery wall. For example, oxidized lipid
epitopes within adipose tissue might attract macrophages,
or particular lipids (or their metabolites) might interfere
with signalling, but this remains to be established.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of patients undergoing
heart-valve surgery
Males Females
n= 14 n= 9
Age (years) 64.8 ± 3.9 68.8 ± 3.3
BMI (kg/m2) 27.2 ± 1.0 26.5 ± 1.3
Glucose (mmol/l) 5.0 ± 0.1 5.2 ± 0.2
HbA1c (%) 4.4 ± 0.1 4.7 ± 0.1*
Insulin (pmol/l) 56.2 ± 10.5 49.6 ± 8.6
Triacylglycerol (mmol/l) 1.2 ± 0.2 0.9 ± 0.1
Total-cholesterol (mmol/l) 5.1 ± 0.2 4.7 ± 0.4
LDL-cholesterol (mmol/l) 3.4 ± 0.2 2.7 ± 0.3
HDL-cholesterol (mmol/l) 1.2 ± 0.1 1.6 ± 0.2*
ALAT (μkat/l) 0.50 ± 0.04 0.41 ± 0.04
γGT (μkat/l) 0.45 ± 0.11 0.48 ± 0.20
CRP (mg/l) 2.9 ± 0.6 2.6 ± 1.0
* P < 0.05 for differences between the groups. Values are expressed as
mean ± SEM. ALAT: alanine aminotransferase; γGT: gamma-glutamyl transferase;
CRP: C-reactive protein.
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of obesity, is of critical importance for the inflammatory
status of adipose tissue [5]. Since fat accumulation in the
liver predicts insulin resistance better than obesity [6], we
postulated previously that hepatic fat content might
distinguish between obese subjects who develop insulin
resistance and adipose tissue inflammation and those who
do not. This hypothesis was supported by investigation of
adipose tissue from obese women with differing liver fat
content [3]. We found greater expression of macrophage-
related genes and lower expression of adiponectin in
subcutaneous adipose tissue from obese women with a
high liver fat content compared to obese women with a
normal liver fat content, but with comparable degrees of
obesity. Furthermore, concentrations of certain ceramides
and sphingomyelins were higher in the inflamed adipose
tissue of women with greater hepatic fat content [3].
Ceramides act as second messengers in numerous
signalling pathways involved in insulin action, inflamma-
tion, angiogenesis and cell death [7,8]. Ceramides are
increased in serum, skeletal muscle and liver of obese
rodents and humans (reviewed in [9]), correlate nega-
tively with insulin sensitivity [10-12] and positively with
circulating IL6 [13] thereby implicating ceramides in the
development of insulin resistance and inflammation. In-
deed, it was recently shown that a lowering of cellular
ceramide mediates adiponectin’s beneficial metabolic
effects [12] and that ceramide links lipid-induced
inflammatory pathways to the development of insulin
resistance [14]. Data on adipose tissue ceramides, which
are more limited and almost entirely restricted to rodent
models, link increased ceramides or ceramide derivatives
in this tissue to obesity, insulin resistance and local in-
flammation [15-20]. Therefore in the current study we
investigate expression and localisation in human adipose
tissue of enzymes involved in ceramide metabolism, with
a particular focus on sphingomyelinases, to understand
better the mechanisms underlying ceramide production




Subcutaneous adipose tissue biopsies were collected
from 20 obese, but otherwise healthy women (age
30–59 years, BMI 30–42 kg/m2), recruited at Helsinki
University Central Hospital, Finland [3]. The women
were divided into two groups according to their liver fat
content as measured by magnetic resonance proton
spectroscopy: normal liver fat (n = 10, liver fat range
1–3.5%) and high liver fat (n = 10, range 6-35%). These
groups were matched for age, BMI and subcutaneous
and intra-abdominal fat masses as determined by MRI.
However, compared to the normal liver fat group, thehigh liver fat group had higher concentrations of cera-
mide and sphingomyelin in subcutaneous adipose tissue
and this tissue was more inflamed, as assessed by signifi-
cantly higher expression levels of CD68, CCL2, CCL3
and PAI-1, and significantly lower expression levels of
adiponectin and PPARG [3].
A second group consisted of 23 non-obese patients
undergoing heart-valve surgery at Karolinska University
Hospital, Stockholm, Sweden, without documented
coronary artery disease. Biopsies were obtained at surgery
from subcutaneous and intra-abdominal adipose tissue,
and from the liver. Blood samples were taken after over-
night fast. Clinical characteristics are summarized in
Table 1. In addition, subcutaneous and intra-abdominal
biopsies were taken at surgery from 8 morbidly obese
patients (2 women, 6 men, age 45± 2 years, BMI
52.6± 2.0 kg/m2) undergoing laparoscopic gastric bypass
operation at Helsinki University Central Hospital.
The nature and potential risks of the study were
explained to all subjects before obtaining written
informed consent. Study protocols were approved by the
ethics committees of Karolinska Institutet and Helsinki
University Central Hospital.
Adipose tissue biopsies
Tissue for gene expression analysis (approximately
150 mg) was either frozen in liquid nitrogen and kept at
−80°C prior to RNA extraction, for biopsies taken from
obese subjects in Helsinki, or fixed in RNA-later
(Ambion), for biopsies taken from patients undergoing
heart-valve surgery in Stockholm. A part of each biopsy
(from the 20 obese women and the 23 patients under-
going heart-valve surgery) was fixed in 4% zinc
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immunohistochemistry. Tissue from the 20 obese women
that had been frozen in liquid nitrogen and preserved at
−80°C was used for lipidomic analysis, as described pre-
viously [3]. In brief, adipose tissue lipids were extracted
using chloroform:methanol (2:1) solvent and analysed
using Ultra Performance Liquid Chromatography coupled
to time-of-flight mass spectrometry (UPLC-QTOFMS). A
total of 154 molecular lipids were measured including the
following sphingolipids: ceramides Cer(d18:0/22:0), Cer
(d18:1/16:0) and Cer(d18:1/24:1); and sphingomyelins SM
(d18:1/16:0), SM(d18:1/18:0), SM(d18:1/20:0), SM(d18:1/
22:0), SM(d18:1/22:1), SM(d18:1/24:1) and SM(d18:1/
24:2). All the identified lipids were quantified by calibrat-
ing with corresponding class-specific internal standards.
Sphingomyelins were calibrated with phosphatidylcholine
PC(17:0/17:0).
RNA isolation and cDNA synthesis
For biopsies collected in Sweden, approximately 150 mg
of adipose tissue was homogenized in Trizol (Invitrogen)
using the Fastprep Homogenizer (Qbiogene). RNA puri-
fication, including DNase treatment, was performed
using RNeasy mini kits (Qiagen) according to the manu-
facturer’s protocol. RNA concentrations were measured
using a NanoDrop spectrophotometer (Thermo). RNA
quality was analyzed by an Agilent Bioanalyzer 2100
(Agilent Technologies). Isolated RNA was stored at −80°C
until cDNA synthesis. A total of 1 μg RNA was tran-
scribed into cDNA using Superscript III reverse tran-
scriptase (Invitrogen) and oligo (dT)12–18 primer. RNA
isolation and cDNA synthesis from biopsies taken in
Finland was described previously [3].
Quantification of gene expression
mRNA expression of specific genes was quantified by
real time PCR using the ABI 7000 Sequence Detection
System instrument and software (Applied Biosystems).
cDNA synthesized from 15 ng of total RNA was mixed
with TaqMan Universal PCR Master Mix (Applied
Biosystems) and a gene-specific primer and probe
mixture (pre-developed TaqMan Gene Expression
Assays, Applied Biosystems) in a final volume of 25 μl.
The assays used were: Hs00154355_m1 for CD68,
Hs00234140_m1 for CCL2, Hs00234142_m1 for CCL3,
Hs00605917_m1 for adiponectin, Hs00174131_m1 for
IL6, Hs00174128_m1 for TNFα, Hs99999910_m1 for
TBP, Hs99999902_m1 for RPLP0 and assays shown in
Table 2. All samples were run in duplicate. Relative ex-
pression levels were determined using a 5-point serially
diluted standard curve, generated from cDNA from
human adipose tissue. Gene expression was expressed in
arbitrary units and normalized relative to the housekeep-
ing genes RPLP0 and TBP to compensate for differencesin cDNA loading. The average of these two values was
used for normalization.
Liver biopsies
RNA extraction, gene expression analysis with Affyme-
trix GeneChip Human Exon 1.0 ST arrays and normal-
isation were performed as described [21]. Of the 23
patients undergoing heart-valve surgery included in the
present study, liver data were available from 21. Hepatic
expression levels of ACSL4, DGAT2, PNPLA3 and
PPARG were selected for subsequent analysis.
Immunohistochemistry
Five μm thick serial sections were deparaffinized and
boiled in TE-buffer (10 mM Tris-Cl, 1 mM EDTA, pH
7.5) at 98°C for 30 min to demask epitopes. After block-
ing with normal serum (goat or horse, Vector Laborator-
ies), sections were incubated with primary antibodies
at 4°C overnight. Primary antibodies were: anti-SMPD1
sc-9815, 1:50, anti-SMPD2 sc-26212, 1:50, anti-SMPD3
sc-67692, 1:50, anti-PECAM-1 sc-1506, 1:100 (all goat
polyclonal IgG, Santa Cruz Biotechnology) and mouse
monoclonal anti-CD68, 1:200 (Novocastra Laboratories),
anti-ASAH1, 1:50 (Abcam) and anti-apolipoprotein B,
1:50 (H61428M Biosite). After washing in PBS buffer, sec-
tions were incubated with secondary biotinylated goat
anti mouse, 1:2000 (Dako) or biotinylated horse anti goat,
1:2000 (Vector Laboratories) antibodies. Staining was
visualized using avidin-biotin peroxidase complex (ABC,
Vector Laboratories) followed by 3.3´-diaminobenzidine
tetrachloride (DAB, Vector Laboratories). All sections
were counterstained with Harris haematoxylin (Histolab).
Collagen was stained with Sirius red (Bie & Berntsen) and
visualized by polar light microscopy.
Statistical analysis
The Statview software (SAS Institute Inc, Cary, NC,
USA) was used. Physical and biochemical characteristics
of the study subjects were analyzed using non-
parametric methods. Groups were compared using the
Mann–Whitney test. Different adipose tissue depots
were compared using the Wilcoxon signed rank test. All
correlations were performed using Spearman’s rank
correlation. Statistical significance was assigned to a
value of P < 0.05. Data are presented as mean± SEM.
Hepatic expression levels of selected genes were used to
generate a mean standard deviation score for hepatic
triacylglycerol accumulation. For each subject, each
value was expressed as standard deviations of difference
from the population mean. The mean hepatic triacylgly-
cerol accumulation score was calculated as the mean of
these standard deviation scores: (ACSL4+DGAT2+
PNPLA3+PPARG)/4.
Table 2 Expression in subcutaneous adipose tissue of
ceramide-metabolising enzymes in relation to adipose
tissue inflammation
















SPTLC1 Hs00272311_m1 27.2 0.99 ± 0.04 1.05 ± 0.06 0.20
SPTLC2 Hs00191585_m1 26.8 0.97 ± 0.07 1.00 ± 0.05 0.39
DEGS1 Hs00186447_m1 25.9 0.99 ± 0.05 1.07 ± 0.05 0.11
LASS1 Hs00242151_m1 33.2 9.07 ± 3.12 9.22 ± 1.63 0.48
LASS4 Hs00226114_m1 27.1 1.08 ± 0.10 1.07 ± 0.16 0.49
LASS6 Hs00826756_m1 28.8 0.87 ± 0.07 0.89 ± 0.07 0.42
ASAH1 Hs00602774_m1 24.3 1.16 ± 0.10 1.47 ± 0.13 0.03
UGCG Hs00234293_m1 28.2 0.91 ± 0.08 0.96 ± 0.06 0.34
SGMS1 Hs00380453_m1 28.0 1.01 ± 0.05 1.10 ± 0.06 0.12
SGMS2 Hs00398067_m1 30.6 2.09 ± 0.27 2.57 ± 0.32 0.13
SMPD1 Hs00609415_m1 26.6 1.51 ± 0.10 1.85 ± 0.10 0.01a
SMPD2 Hs00162006_m1 29.8 1.13 ± 0.06 1.26 ± 0.06 0.08 a
SMPD3 Hs00218713_m1 33.8 1.33 ± 0.13 1.76 ± 0.18 0.05 a
SMPD4 Hs00215775_m1 29.1 1.57 ± 0.09 1.52 ± 0.09 0.35
CERK Hs00368483_m1 29.3 1.57 ± 0.15 1.87 ± 0.10 0.06
SPHK1 Hs00184211_m1 28.9 12.18 ± 1.49 17.64 ± 1.65 0.01
CGT Hs00409961_m1 35.5 4.45 ± 1.29 3.45 ± 0.52 0.24
CDH5 Hs00174344_m1 28.3 1.16 ± 0.14 1.43 ± 0.13 0.09
SELE Hs00950401_m1 33.2 0.72 ± 0.15 2.45 ± 0.94 0.04
VEGF Hs0090054_m1 26.4 4.13 ± 0.37 3.71 ± 0.52 0.25
HIF-1α Hs00153153_m1 27.6 1.39 ± 0.12 1.65 ± 0.08 0.02
Relative gene expression levels of genes involved in ceramide and
sphingomyelin metabolism in subcutaneous adipose tissue of obese women
with different degrees of adipose tissue inflammation are given. SPTLC: serine
palmitoyl transferase long-chain; DEGS: dihydroceramide desaturase; LASS:
LAG1 homolog (ceramide synthase); ASAH: N-acylsphingosine amidohydrolase
(ceramidase); UGCG: UDP-glucose ceramide glucosyltransferase; SGMS:
sphingomyelin synthase; SMPD: sphingomyelin phosphodiesterase
(sphingomyelinase); CERK: ceramide kinase; SPHK: sphingosine kinase; CGT:
ceramide glycosyl transferase; CDH5: cadherin 5 (vascular endothelium); SELE:
selectin E; VEGF: vascular endothelial growth factor; HIF-1α: hypoxia-inducible
factor 1α. Gene expression was normalized to housekeeping genes RPLP0 and
TBP, which did not differ between the groups (for RPLP0: 1.94 ± 0.26 vs
2.11 ± 0.17, NS; for TBP: 3.96 ± 0.48 vs 3.97 ± 0.44, NS). Values are expressed as
mean ± SEM. a Reported previously [3].
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To investigate the basis for elevated ceramide/sphingomyelin
concentrations in inflamed adipose tissue, expression
levels of genes involved in ceramide synthesis and me-
tabolism (summarised in Figure 1) were quantified in
subcutaneous adipose tissue from obese women. These
women were divided into two groups based on their
liver fat content: normal (2.3 ± 0.3%, n = 10) and high
(14.4 ± 2.9%, n = 10). The groups were similar with re-
spect to age, BMI and subcutaneous and intra-
abdominal adipose tissue masses, but the high liver fatgroup had a more unfavourable metabolic profile and
more inflammation and higher ceramide and sphingo-
myelin concentrations in their subcutaneous adipose
tissue [3]. Genes involved in de novo ceramide synthesis
(SPTLC1, SPTLC2, DEGS1, LASS1, LASS4 and LASS6)
were not differentially expressed between the groups
(Table 2). Ceramide-metabolising enzymes CGT, CERK,
SGMS1, SGMS2 and UGCG were also similarly
expressed. However, ASAH1 and SPHK1 were expressed
at significantly higher levels in the women with more
inflamed adipose tissue (P= 0.03 and P= 0.01, respect-
ively). Expression levels of three sphingomyelinases were
greater (P= 0.01 for SMPD1, P= 0.05 for SMPD3), or
tended to be greater (P= 0.08 for SMPD2) in the women
with high liver fat and more inflammation and higher
ceramide/sphingomyelin content in their adipose tissue
[3], but expression of a fourth sphingomyelinase,
SMPD4, did not differ.
To establish whether ceramide and sphingomyelin
metabolising enzymes that displayed differential mRNA
expression between the two groups, namely SMPD1,
SMPD2, SMPD3, ASAH1 and SPHK1, might be deter-
minants of ceramide and/or sphingomyelin concentra-
tions in adipose tissue, their mRNA levels were
correlated with these lipid species (Table 3). Expression
levels of SMPD3 in adipose tissue were statistically
significantly correlated with 2 out of the 3 ceramides
and 6 out of the 7 sphingomyelins that were quantified
with the lipidomic analysis. SPHK1 expression was sig-
nificantly correlated with one ceramide and two
sphingomyelin species.
Collectively these data suggested a possible role for
sphingomyelinase activity in adipose tissue in determining
adipose ceramide and/or sphingomyelin concentrations,
which may be related to inflammation and macrophage
accumulation. To establish the location of these enzymes
in adipose tissue, immunohistochemical analysis of
subcutaneous adipose tissue from the obese women was
performed. SMPD1-3 proteins were expressed in both
macrophages and adipocytes within adipose tissue
(Figure 2). All three sphingomyelinases were also found
in and around blood vessels (Figure 2F-H).
To investigate sphingomyelinases further in human
adipose tissue, the mRNA expression and protein distri-
bution of SMDP1-3 was compared in subcutaneous and
intra-abdominal adipose tissue from non-obese indivi-
duals (clinical characteristics in Table 1). Gene expres-
sion levels of the inflammatory markers CD68, CCL2
and IL6 were significantly higher in intra-abdominal
compared to subcutaneous fat (Figure 3A). SMPD3
mRNA was higher, while expression of SMPD2 was
lower in intra-abdominal compared to subcutaneous fat.
Expression of SMPD1 was similar in both depots.
Immunohistochemical analysis of subcutaneous and
Figure 1 Schematic diagram depicting enzymatic reactions involved in the synthesis and degradation of ceramide and sphingomyelin.
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teins mainly to blood vessels (Figure 4A and C for
SMPD3). Furthermore, an enzyme that metabolises cera-
mides, ASAH1, was also localized to the vasculature
(Figure 4E). In light of our previous data from obese
women identifying a relationship between inflammation
and ceramide metabolism in adipose tissue and fat accu-
mulation in the liver, we investigated associations be-
tween gene expression in adipose tissue and liver in
these non-obese individuals. Since direct measurements
of liver fat were not available, hepatic mRNA levels of
selected genes were used as surrogate markers of liver
fat accumulation. Due to the small sample size, only a
very limited number of genes were selected: ACSL4,
DGAT2, PNPLA3 and PPARG. We have previously
shown hepatic expression of ACSL4 and PPARG to be
related to liver fat content [22]. DGAT catalyses thecommitted step in triacylglycerol synthesis with DGAT2
being the dominant DGAT enzyme controlling triacyl-
glycerol homeostasis in vivo [23], and PNPLA3 has been
implicated in the development of hepatic steatosis [24].
A mean standard deviation score was calculated from the
hepatic mRNA expression data for these 4 genes (see
methods) to generate a summary score for liver triacylgly-
cerol accumulation. This liver summary score was signifi-
cantly correlated to expression levels of CD68 (chosen as a
marker of macrophage accumulation) in both subcutane-
ous and intra-abdominal adipose tissue (r = 0.56, P=0.01
and r = 0.49 P=0.03 respectively), but not to adipose tissue
sphingomyelinase expression in either depot (SMPD1:
r = 0.10, P=0.65 and r = 0.24, P=0.29; SMPD2: r = 0.16,
P=0.48 and r = 0.33, P=0.14; and SMPD3: r = 0.10,
P=0.65 and r = 0.21, P=0.36 for subcutaneous and intra-
abdominal adipose tissue respectively).
Table 3 Correlations between sphingomyelinase, ceramidase and sphingosine kinase gene expression, and ceramide
and sphingomyelin concentrations in subcutaneous adipose tissue
SMPD1 SMPD2 SMPD3 ASAH1 SPHK1
r P r P r P r P r P
Cer(d18:0/22:0) 0.380 0.097 −0.170 0.459 0.244 0.288 0.005 0.984 0.259 0.260
Cer(d18:1/16:0) 0.065 0.778 0.089 0.699 0.498 0.030 0.047 0.839 0.361 0.116
Cer(d18:1/24:1) 0.408 0.076 0.283 0.218 0.552 0.016 0.344 0.133 0.526 0.022
SM(d18:1/16:0) 0.135 0.555 0.020 0.932 0.211 0.359 −0.310 0.177 −0.203 0.376
SM(d18:1/18:0) 0.281 0.220 0.411 0.074 0.496 0.031 −0.164 0.475 0.215 0.349
SM(d18:1/20:0) 0.398 0.082 0.376 0.101 0.555 0.016 −0.338 0.140 0.492 0.032
SM(d18:1/22:0) 0.331 0.149 0.356 0.120 0.595 0.009 0.075 0.743 0.474 0.039
SM(d18:1/22:1) 0.415 0.070 0.290 0.206 0.582 0.011 −0.081 0.723 0.445 0.052
SM(d18:1/24:1) 0.253 0.271 0.423 0.066 0.567 0.014 0.167 0.467 0.289 0.208
SM(d18:1/24:2) 0.329 0.151 0.319 0.165 0.513 0.025 −0.033 0.885 0.405 0.078
Correlations between gene expression levels of SMPD1-3 (sphingomyelinases), ASAH1 (ceramidase) and SPHK1 (sphingosine kinase) and concentrations of various
ceramides (cer) and sphingomyelins (SM) in subcutaneous adipose tissue of obese women (n = 20). Spearman rank correlation coefficients and significance levels
are shown. Comparison of sphingolipid concentrations (mean ± SEM, nmol/g adipose tissue) in subcutaneous adipose tissue from women with less inflamed
adipose tissue/normal liver fat (n = 10) versus more inflamed adipose tissue/high liver fat content (n = 10), as reported previously [3]: Cer(d18:0/22:0): 3.80 ± 0.58 vs
6.21 ± 1.11, P= 0.076; Cer(d18:1/16:0): 2.66 ± 0.28 vs 3.12 ± 0.23, P= 0.219; Cer(d18:1/24:1): 5.36 ± 0.47 vs 7.97 ± 0.70, P= 0.006; SM(d18:1/16:0): 36.86 ± 2.64 vs
35.10 ± 2.64, P= 0.643; SM(d18:1/18:0): 4.88 ± 0.40 vs 6.02 ± 0.46, P= 0.077; SM(d18:1/20:0): 5.84 ± 0.50 vs 7.30 ± 0.52, P= 0.055; SM(d18:1/22:0): 11.38 ± 0.96 vs
15.38 ± 1.15, P= 0.015; SM(d18:1/22:1): 7.13 ± 0.54 vs 8.54 ± 0.67, P= 0.121; SM(d18:1/24:1): 17.00 ± 1.33 vs 22.96 ± 1.70, P= 0.013; SM(d18:1/24:2): 7.42 ± 0.56 vs
9.69 ± 0.76, P= 0.028. Lipidomic analysis was described previously [3].
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taneous and intra-abdominal adipose tissue were also
determined in an independent group of 8 morbidly
obese subjects (Figure 3B). Levels of SMPD3 mRNA
were significantly greater in intra-abdominal than in
subcutaneous adipose tissue, but no significant differ-
ences were observed for SMPD1 or SMPD2. Differences
in gene expression between adipose tissue depots could
not be explained by depot-specific differences in house-
keeping gene expression and essentially identical results
were obtained when non-normalised gene expression
data (raw Ct values) were used (data not shown).
Since staining for sphingomyelinases in adipose tissue
was strongest in the vicinity of blood vessels, we investi-
gated whether there were differences in adipose tissue
vascularity between women with more or less inflamma-
tion in their adipose tissue. However, expression levels
of a marker of vascular endothelium (CDH5) did not
differ between groups (Table 2). Expression levels of
markers of hypoxia (HIF-1α) and endothelial activation
(E-selectin) were significantly higher in the adipose
tissue of women with an increased liver fat content and
more inflammation and higher ceramide concentrations
in their adipose tissue (Table 2), but these increases in
hypoxia and endothelial activation did not appear to be
associated with an increase in angiogenesis, since there
was no corresponding increase in expression of the mar-
ker for endothelial growth, VEGF. In adipose tissue from
both obese and non-obese subjects, staining for the inte-
gral protein of hepatic lipoproteins, apolipoprotein B
(apo B), was found in blood vessels, but also in regionsthat stained positive for CD68 (Figure 5), suggesting that
lipoproteins entering adipose tissue via the vasculature
might provide a source of sphingomyelins for hydrolysis
by local sphingomyelinases to produce ceramide.
Discussion
We investigated sphingolipid metabolism in human adi-
pose tissue to identify pathways underlying increased
ceramide concentrations in inflamed adipose tissue [3].
Our data suggest that hydrolysis of sphingomyelin to
ceramide by sphingomyelinases could explain, at least
partly, this increase. Gene expression levels of SMPD3
correlate significantly with concentrations of various
ceramides and sphingomyelins in subcutaneous adipose
tissue, and are higher in the relatively more inflamed
intra-abdominal compared to the subcutaneous depot in
both obese and non-obese subjects. Sphingomyelinases
are expressed by both adipocytes and macrophages in
adipose tissue, but their expression is strongest in and
around blood vessels. Our findings implicate a role for
sphingomyelinase-mediated generation of ceramide in
adipose tissue inflammation.
When comparing inflamed ceramide-rich and rela-
tively less inflamed ceramide-poor subcutaneous adipose
tissue of obese women, we report here for the first time
that there were no differences in mRNA levels of genes
involved in de novo ceramide synthesis. However, ex-
pression of sphingomyelinases SMPD1 and SMPD3 was
significantly higher, while that of SMPD2 tended to be
higher in the inflamed adipose tissue group (as reported






Figure 2 Localisation of sphingomyelinases in subcutaneous
adipose tissue. Representative pictures of immunohistochemical
staining of macrophages and multinuclear giant cells (aggregated
macrophages) (A-D) and a small blood vessel (E-J) within
subcutaneous adipose tissue from an obese woman. Brown
coloration indicates macrophage-specific CD68 (A and E), SMPD1
(B and F), SMPD2 (C and G), SMPD3 (D and H) and PECAM-1 (I). All
sections were counterstained with haematoxylin (coloured blue).
Collagen staining (J) was visualized with polarized light to reveal
mature, extracellular collagen (coloured red).
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http://www.lipidworld.com/content/11/1/115sphingomyelins to ceramide, this pathway rather than
de novo ceramide synthesis, may underlie the increased
ceramide content of the inflamed adipose tissue of these
women. Sphingomyelinase activity is increased byoxidative stress both in vitro [25] and in vivo [26] and
sphingomyelinase expression in adipose tissue increases
in response to a high fat diet in mouse models [15,27].
Since ceramides stimulate synthesis of pro-inflammatory
cytokines by both adipocytes and macrophages [27,28],
increased sphingomyelinase activity in adipose tissue
could exacerbate the inflammatory milieu and enhance
recruitment of macrophages. Therefore investigation of
sphingomyelinases in human adipose tissue in relation
to inflammation and macrophage accumulation is moti-
vated. To date the only report of sphingomyelinases in
human adipose tissue found reduced acid sphingomyeli-
nase, but unchanged neutral sphingomyelinase activity
in obese compared to lean patients [29].
Although we observed increased sphingomyelinase
mRNA expression in inflamed adipose tissue, sphingo-
myelinases did not localise only to inflammatory cells
(determined by immunohistochemistry). Staining for
SMPD1, -2 and −3 was seen in macrophages and also in
adipocytes, but the strongest staining was seen in and
around blood vessels, the latter being reminiscent of the
secretory form of SMPD1 localising to the subendothe-
lial matrix of atherosclerotic lesions [30]. Additionally,
the ceramide-metabolising enzyme ASAH1 was found in
the vasculature, indicating that blood vessels are import-
ant sites for ceramide metabolism within adipose tissue.
Indeed, immunohistochemical analysis revealed staining
for apo B in areas containing inflammatory cells (posi-
tive for CD68) and within blood vessels, indicating
access of adipose tissue sphingomyelinases to sphingo-
myelins within lipoproteins. Previously we found that
not only ceramides, but also sphingomyelins were
increased in adipose tissue of obese women with more
inflamed adipose tissue. The increase in sphingomyelins
did not appear to be accounted for by increased local
synthesis (as discussed above), but might be explained
by an increased delivery of sphingomyelin-rich lipopro-
teins produced by fatty liver [31], since these women
also had increased hepatic fat content, but quantification
of lipoprotein delivery to or retention within adipose tis-
sue was not possible in this study. To pursue this idea
we investigated the relationship between hepatic triacyl-
glycerol accumulation and adipose tissue ceramide me-
tabolism and inflammation in non-obese individuals.
Inflammation in both subcutaneous and intra-abdominal
adipose tissue (as assessed by RNA levels of the macro-
phage marker CD68) was positively related to the
expression of genes in the liver reflecting triacylglycerol
accumulation, but no such relationships were found for
sphingomyelinase expression (SMPD1, -2 or −3) in
either adipose tissue depot. This suggests that even in
non-obese individuals, the number of macrophages
within adipose tissue is linked to hepatic triacylglycerol










































Figure 3 Gene expression in subcutaneous and intra-abdominal adipose tissue from non-obese and obese individuals. (A) Relative gene
expression levels of SMPD1-3, CD68, CCL2, CCL3, TNFα, IL6 and adiponectin in subcutaneous (black bars) and intra-abdominal (white bars)
adipose tissue from 23 non-obese individuals. (B) Relative gene expression levels of SMPD1-3 in subcutaneous (black bars) and intra-abdominal
(white bars) adipose tissue from 8 obese patients. Expression is in arbitrary units normalized to housekeeping genes RPLP0 and TBP, and set to 1
for the subcutaneous depot. * P< 0.05, ** P <0.01, *** P< 0.001 compared to subcutaneous adipose tissue.
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fortunately no measurements of either adipose tissue
ceramide concentrations or liver fat content were available,
so no conclusions can be drawn as to the relationship be-
tween adipose tissue macrophage accumulation, ceramide
concentration and hepatic triacylglycerol content, but our
data suggest that sphingomyelinase-mediated generation of
ceramide in adipose tissue does not play a major role in this
context in non-obese subjects who are unlikely to have fatty
livers.
Our data highlighted the potential importance of
SMPD3 within adipose tissue in relation to ceramidegeneration and inflammation for two reasons. Firstly,
mRNA levels of SMPD3 correlated significantly with
ceramide and sphingomyelin concentrations within adi-
pose tissue of obese women. Secondly, a relatively more
inflamed adipose tissue depot, namely intra-abdominal
fat, expressed SMPD3 mRNA at significantly greater
levels than relatively less inflamed subcutaneous adipose
tissue in both non-obese and obese subjects. It is pos-
sible that increased SMPD3 activity contributes to the
greater ceramide concentrations in intra-abdominal
compared to subcutaneous adipose tissue [32]. Adipose




A Figure 4 Localisation of sphingomyelinase SMPD3 andceramidase ASAH1 in subcutaneous and intra-abdominal
adipose tissue. Representative pictures of immunohistochemical
staining of a vessel within subcutaneous (A, B and E) and intra-
abdominal (C and D) adipose tissue from a non-obese individual.
Positive staining for SMPD3 (A and C) and ASAH1 (E) is shown as
brown coloration. Negative staining is shown in panels B and D. All
sections were counterstained with haematoxylin (coloured blue).
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ciated with obesity, promoting macrophage infiltration
and angiogenesis [33]. The location of sphingomyeli-
nases to blood vessels within adipose tissue might indi-
cate their involvement in angiogenesis. The increased
expression of markers of hypoxia and endothelial activa-
tion, but no differences in markers of either angiogenesis
or endothelial cell number in adipose tissue of women
with inflamed compared to less inflamed adipose tissue,
indicates the existence of hypoxia and an activated endo-
thelium without an apparent decrease in vessel density
or onset of angiogenesis. It is possible that the increased
degree of inflammation is related to an inability of
hypoxia and increased ceramide concentrations to in-
duce angiogenesis within adipose tissue. Since particular
importance was assigned to SMPD3 in hypoxic vasocon-
striction in the lung [34], SMPD3 may play a role linking
hypoxia, ceramide generation and inflammation within
adipose tissue, however, this remains to be shown.
The observation that concentrations of some ceramide
and sphingomyelin species correlated positively with
gene expression levels of SPHK1 (sphingosine kinase) in
adipose tissue in the cohort of obese women is also of
interest. The product of SPHK1 action is sphingosine-
1-phosphate (concentrations of which were not quanti-
fied in the present study), a sphingolipid that appears to
have the opposite actions to that of ceramide, namely
promoting cell survival and proliferation [35]. Indeed,
the balance between concentrations of ceramide and
sphingosine-1-phosphate is proposed to be an important
mechanism controlling cell fate [35]. One interpretation
of our data could be that the higher expression levels of
SPHK1 in the more inflamed adipose tissue of the
women with fatty livers, as compared to the less
inflamed adipose tissue of women with normal liver fat
content, and the correlations between SPHK1 expression
and ceramide/sphingomyelin concentrations in the
cohort as a whole reflect a protective mechanism to
counteract the potentially detrimental consequences of
ceramide accumulation, but this is speculative and future
studies are needed to investigate this.
Strengths of our study include the investigation of
human adipose tissue biopsies from three independent
patient groups and two different depots, and the avail-
ability of measures of hepatic fat content in the obese
BA
C
Figure 5 Localisation of apo B in subcutaneous and intra-
abdominal adipose tissue. Representative pictures of
immunohistochemical staining of apo B (A, C) and CD68 (B) in
human adipose tissue. (A) and (B): Serial sections of subcutaneous
adipose tissue from an obese woman stained for apo B and CD68
respectively. (C): Intra abdominal adipose tissue from a non-obese
individual stained for apo B. Positive staining for apo B (A and C)
and CD68 (B) is shown as brown coloration. All sections were
counterstained with haematoxylin (coloured blue).
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obese subjects enabling us to investigate relationships
between liver and adipose tissue. A limitation is that
comparisons between the different patient groupscannot be made since the groups were not anlaysed at
the same time, thus only within group comparisons can
be made. Another limitation is the availability of only
mRNA quantification of sphingomyelinase expression
rather than protein concentration or enzyme activity.
Nonetheless, protein expression of sphingomyelinase
was confirmed and its location in adipose tissue estab-
lished by immunohistochemistry. The small size of the
biopsies obtained precluded more extensive analysis. Ana-
lysis of only adipocytes was not performed since we
aimed to explore the expression of ceramide-metabolising
enzymes in adipose tissue as a whole (including inflam-
matory cells, connective tissue, blood vessels etc.) rather
than exclusively in adipocytes. However, immunohisto-
chemical analysis provided information as to the cellular
location of certain proteins.
Conclusions
Our data suggest that sphingomyelinase-mediated produc-
tion of ceramide from sphingomyelin may be one mecha-
nism contributing to the development of inflammation
within human adipose tissue. An increased expression of
SMPD3 in inflamed adipose tissue and in intra-abdominal
compared to subcutaneous tissue, and its close association
with adipose tissue ceramide levels might indicate an im-
portant role for this sphingomyelinase.
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